StreetInsider.com News Articles

TD Cowen Assumes Cabaletta Bio (CABA) at Buy

Sat, 22 Aug 2026 07:55:00 -0400

TD Cowen analyst Phil Nadeau assumes coverage on Cabaletta Bio (NASDAQ: CABA) with a Buy rating.

For an analyst ratings summary and ratings history on Cabaletta Bio click here. For more ratings news on Cabaletta Bio click here.

Shares of Cabaletta Bio closed at $3.13 yesterday.

Form SCHEDULE 13G/A Cabaletta Bio, Inc. Filed by: Cormorant Asset Management, LP

Fri, 14 Aug 2026 14:01:00 -0400

si-local-file:///var/storage/secattach/20260814/26928704.html

Form SCHEDULE 13G/A Cabaletta Bio, Inc. Filed by: Cormorant Asset Management, LP

Fri, 14 Aug 2026 14:01:00 -0400

si-local-file:///var/storage/secattach/20260814/26928704.html

Form SCHEDULE 13G/A Cabaletta Bio, Inc. Filed by: T. Rowe Price Investment Management, Inc.

Fri, 14 Aug 2026 10:40:00 -0400

si-local-file:///var/storage/secattach/20260814/26926656.html

Form SCHEDULE 13G/A Cabaletta Bio, Inc. Filed by: T. Rowe Price Investment Management, Inc.

Fri, 14 Aug 2026 10:40:00 -0400

si-local-file:///var/storage/secattach/20260814/26926656.html

Cabaletta Bio (CABA) PT Lowered to $3 at Wells Fargo

Fri, 14 Aug 2026 08:51:55 -0400

Wells Fargo analyst Derek Archila lowered the price target on Cabaletta Bio (NASDAQ: CABA) to $3.00 (from $4.00) while maintaining a Equal Weight rating.

Form SCHEDULE 13G/A Cabaletta Bio, Inc. Filed by: Bain Capital Life Sciences Opportunities III, LP

Fri, 14 Aug 2026 07:00:00 -0400

si-local-file:///var/storage/secattach/20260814/26924420.html

Form SCHEDULE 13G/A Cabaletta Bio, Inc. Filed by: Bain Capital Life Sciences Opportunities III, LP

Fri, 14 Aug 2026 07:00:00 -0400

si-local-file:///var/storage/secattach/20260814/26924420.html

TD Cowen: 'CABA appears well-positioned to scale commercially with minimal capital investment'

Thu, 13 Aug 2026 10:32:03 -0400

TD Cowen analyst Phil Nadeau reiterated a Buy rating on Cabaletta Bio (NASDAQ: CABA).

The analyst comments "Cabaletta continues to execute across its portfolio of RESET trials. The RESET-Myositis pivotal trial is on track for data Mid:27 with a BLA including juveniles in H2:27. Notably, data presented at EULAR (detailed here) supports pivotal development of rese-cel in SSc-associated ILD and juvenile myositis. Recall, rese-cel treatment in SSc-ILD patients led to a median FVC improvement of ~8% at 26 weeks, in contrast to SoC agents that slow decline but are not associated with improvement. This appears to be a meaningful potential advance,

Form 10-Q Cabaletta Bio, Inc. For: Jun 30

Thu, 13 Aug 2026 07:35:00 -0400

si-local-file:///var/storage/secattach/20260813/26916538.html

Form 10-Q Cabaletta Bio, Inc. For: Jun 30

Thu, 13 Aug 2026 07:35:00 -0400

si-local-file:///var/storage/secattach/20260813/26916538.html

Form 8-K Cabaletta Bio, Inc. For: Aug 13

Thu, 13 Aug 2026 07:32:00 -0400

si-local-file:///var/storage/secattach/20260813/26916529.html

Form 8-K Cabaletta Bio, Inc. For: Aug 13

Thu, 13 Aug 2026 07:32:00 -0400

si-local-file:///var/storage/secattach/20260813/26916529.html

Cabaletta Bio Reports Second Quarter 2026 Financial Results and Provides Business Update

Thu, 13 Aug 2026 07:30:00 -0400

Registrational RESET-Myositis^® clinical data on track to be reported in mid-2027 to support 2H27 BLA submission for rese-cel

Juvenile myositis Phase 1/2 data expected to be submitted with BLA to support potential FDA Priority Review Voucher

Registrational RESET-SSc^® enrollment in approximately 25 patients with SSc-associated interstitial lung disease anticipated to initiate in 4Q26

PC-free approach being incorporated in RESET-MG^® based on emerging insights from PC-free RESET-SLE^® and RESET-PV^® cohorts and previously reported Phase 1/2 clinical data

Pursuing expansion of outpatient dosing option for rese-cel within the RESET™ clinical development program

Cabaletta Bio Reports Second Quarter 2026 Financial Results and Provides Business Update

Thu, 13 Aug 2026 07:30:00 -0400

Registrational RESET-Myositis^® clinical data on track to be reported in mid-2027 to support 2H27 BLA submission for rese-cel

Juvenile myositis Phase 1/2 data expected to be submitted with BLA to support potential FDA Priority Review Voucher

Registrational RESET-SSc^® enrollment in approximately 25 patients with SSc-associated interstitial lung disease anticipated to initiate in 4Q26

PC-free approach being incorporated in RESET-MG^® based on emerging insights from PC-free RESET-SLE^® and RESET-PV^® cohorts and previously reported Phase 1/2 clinical data

Pursuing expansion of outpatient dosing option for rese-cel within the RESET™ clinical development program

Cabaletta Bio Reports Second Quarter 2026 Financial Results and Provides Business Update

Thu, 13 Aug 2026 07:30:00 -0400

Registrational RESET-Myositis^® clinical data on track to be reported in mid-2027 to support 2H27 BLA submission for rese-cel

Juvenile myositis Phase 1/2 data expected to be submitted with BLA to support potential FDA Priority Review Voucher

Registrational RESET-SSc^® enrollment in approximately 25 patients with SSc-associated interstitial lung disease anticipated to initiate in 4Q26

PC-free approach being incorporated in RESET-MG^® based on emerging insights from PC-free RESET-SLE^® and RESET-PV^® cohorts and previously reported Phase 1/2 clinical data

Pursuing expansion of outpatient dosing option for rese-cel within the RESET™ clinical development program

Cabaletta Bio Reports Second Quarter 2026 Financial Results and Provides Business Update

Thu, 13 Aug 2026 07:30:00 -0400

Registrational RESET-Myositis^® clinical data on track to be reported in mid-2027 to support 2H27 BLA submission for rese-cel

Juvenile myositis Phase 1/2 data expected to be submitted with BLA to support potential FDA Priority Review Voucher

Registrational RESET-SSc^® enrollment in approximately 25 patients with SSc-associated interstitial lung disease anticipated to initiate in 4Q26

PC-free approach being incorporated in RESET-MG^® based on emerging insights from PC-free RESET-SLE^® and RESET-PV^® cohorts and previously reported Phase 1/2 clinical data

Pursuing expansion of outpatient dosing option for rese-cel within the RESET™ clinical development program

Form SCHEDULE 13G/A Cabaletta Bio, Inc. Filed by: Adage Capital Management, L.P.

Wed, 12 Aug 2026 12:06:00 -0400
si-local-file:///var/storage/secattach/20260812/26911248.html

Form SCHEDULE 13G/A Cabaletta Bio, Inc. Filed by: Adage Capital Management, L.P.

Wed, 12 Aug 2026 12:06:00 -0400
si-local-file:///var/storage/secattach/20260812/26911248.html

Form SCHEDULE 13G Cabaletta Bio, Inc. Filed by: NORGES BANK

Wed, 12 Aug 2026 06:36:00 -0400
si-local-file:///var/storage/secattach/20260812/26908525.html

Form SCHEDULE 13G Cabaletta Bio, Inc. Filed by: NORGES BANK

Wed, 12 Aug 2026 06:36:00 -0400
si-local-file:///var/storage/secattach/20260812/26908525.html

Form SCHEDULE 13G Cabaletta Bio, Inc. Filed by: VANGUARD CAPITAL MANAGEMENT LLC

Fri, 31 Jul 2026 09:55:00 -0400
si-local-file:///var/storage/secattach/20260731/26847978.html

Form SCHEDULE 13G Cabaletta Bio, Inc. Filed by: VANGUARD CAPITAL MANAGEMENT LLC

Fri, 31 Jul 2026 09:55:00 -0400
si-local-file:///var/storage/secattach/20260731/26847978.html

Form SCHEDULE 13G Cabaletta Bio, Inc. Filed by: BlackRock, Inc.

Mon, 27 Jul 2026 16:27:00 -0400
si-local-file:///var/storage/secattach/20260727/26819975.html

Form SCHEDULE 13G Cabaletta Bio, Inc. Filed by: BlackRock, Inc.

Mon, 27 Jul 2026 16:27:00 -0400
si-local-file:///var/storage/secattach/20260727/26819975.html